Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

NCT01046916 ·Status: COMPLETED ·Phase: PHASE2

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05520138 ·Status: COMPLETED

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665 ·Status: RECRUITING ·Phase: PHASE1

Study Using CP-461 to Treat Advanced Prostate Cancer

NCT00036075 ·Status: COMPLETED ·Phase: PHASE2

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

NCT03570476 ·Status: TERMINATED ·Phase: PHASE2

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

NCT05701007 ·Status: COMPLETED

A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer

NCT05567679 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

NCT03690141 ·Status: TERMINATED ·Phase: PHASE2

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

NCT03674814 ·Status: COMPLETED ·Phase: PHASE1

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2

NCT05579184 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

NCT02566772 ·Status: COMPLETED ·Phase: PHASE1

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05425862 ·Status: SUSPENDED ·Phase: PHASE1

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

NCT06582628 ·Status: RECRUITING ·Phase: PHASE2

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

NCT04332744 ·Status: COMPLETED ·Phase: PHASE2

A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

NCT06733337 ·Status: ACTIVE_NOT_RECRUITING

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

NCT05401214 ·Status: APPROVED_FOR_MARKETING

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

NCT05873192 ·Status: RECRUITING ·Phase: PHASE2

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06033001 ·Status: TEMPORARILY_NOT_AVAILABLE

A Research Study for Patients With Prostate Cancer

NCT00106418 ·Status: COMPLETED ·Phase: PHASE2

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03137758 ·Status: TERMINATED ·Phase: PHASE1

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

NCT00140478 ·Status: COMPLETED ·Phase: PHASE2

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

NCT00585416 ·Status: TERMINATED ·Phase: PHASE2